| 17.515 1.555 (9.74%) | 06-01 13:17 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 25.2  |
1-year : | 29.87 |
| Resists | First : | 21.57 |
Second : | 25.57 |
| Pivot price | 17.14 |
|||
| Supports | First : | 15.1 |
Second : | 12.56 |
| MAs | MA(5) : | 16.51 |
MA(20) : | 17.82 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | -1 |
Signal : | -1 |
| %K %D | K(14,3) : | 22.8 |
D(3) : | 16.1 |
| RSI | RSI(14): 47.6 |
|||
| 52-week | High : | 26.79 | Low : | 14.78 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ TRAX ] has closed below upper band by 37.8%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 16.55 - 16.65 | 16.65 - 16.75 |
| Low: | 15.03 - 15.14 | 15.14 - 15.25 |
| Close: | 15.78 - 15.95 | 15.95 - 16.11 |
First Tracks Biotherapeutics, Inc. engages in the research and development of immunology therapeutics for autoimmune and inflammatory diseases. It focuses on clinical-stage programs for rosnilimab, ANB033 and ANB101. The company is headquartered in San Diego, CA.
Mon, 01 Jun 2026
First Tracks Biotherapeutics (TRAX) Stock Trends and Sentiment 2026 $TRAX - MarketBeat
Sun, 31 May 2026
First Tracks Biotherapeutics (TRAX) Stock Forecast and Price Target 2026 $TRAX - MarketBeat
Thu, 28 May 2026
TRAX Price Today: First Tracks Biotherapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Thu, 21 May 2026
Autoimmune drug biotech First Tracks to meet investors at Jefferies, Leerink - Stock Titan
Thu, 21 May 2026
First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences - Yahoo Finance
Thu, 14 May 2026
Director at First Tracks Biotherapeutics (TRAX) granted options and RSUs - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 35 (M) |
| Shares Float | 31 (M) |
| Held by Insiders | 6.5 (%) |
| Held by Institutions | 42.7 (%) |
| Shares Short | 4,030 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.72 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.38 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -4.01 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -5.16 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -130 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -3.74 |
| PEG Ratio | 0 |
| Price to Book value | 2.38 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.71 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|